Entrada Therapeutics Newsroom

Oppenheimer Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Raises Target Price to $28

Moomoo NewsNov 6 08:37 ET

Oppenheimer Adjusts Entrada Therapeutics Price Target to $28 From $25, Maintains Outperform Rating

MT NewswiresNov 6 08:33 ET

Entrada Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow JonesNov 6 07:46 ET

Entrada Therapeutics Analyst Ratings

BenzingaNov 6 07:37 ET

H.C. Wainwright Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Raises Target Price to $20

Moomoo NewsNov 6 06:33 ET

TD Cowen Maintains Entrada Therapeutics(TRDA.US) With Buy Rating

Moomoo NewsNov 5 10:31 ET

TD Cowen Sticks to Its Buy Rating for Entrada Therapeutics Inc (TRDA)

TipRanksNov 5 10:11 ET

Entrada Therapeutics Analyst Ratings

BenzingaAug 26 10:55 ET

Oppenheimer Initiates Entrada Therapeutics(TRDA.US) With Buy Rating, Announces Target Price $25

Moomoo NewsAug 26 08:32 ET

TD Cowen Maintains Entrada Therapeutics(TRDA.US) With Buy Rating

Moomoo NewsAug 14 08:33 ET

H.C. Wainwright Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Maintains Target Price $18

Moomoo NewsAug 14 07:31 ET

Entrada Therapeutics Analyst Ratings

BenzingaAug 14 06:56 ET

Buy Rating Affirmed for Entrada Therapeutics on Strong Clinical Trial Data and Regulatory Prospects

TipRanksAug 14 06:44 ET

TD Cowen Maintains Entrada Therapeutics(TRDA.US) With Buy Rating

Moomoo NewsAug 13 17:31 ET

TD Cowen Keeps Their Buy Rating on Entrada Therapeutics Inc (TRDA)

TipRanksAug 13 16:57 ET

Entrada Therapeutics Analyst Ratings

BenzingaJun 25 06:50 ET

Entrada Therapeutics Analyst Ratings

BenzingaMar 18 06:38 ET

TD Cowen Reaffirms Their Buy Rating on Entrada Therapeutics Inc (TRDA)

TipRanksMar 13 10:30 ET

Oppenheimer Initiates Coverage On Entrada Therapeutics With Outperform Rating, Announces Price Target of $22

BenzingaJan 5 07:23 ET

Entrada Therapeutics Analyst Ratings

BenzingaJan 5 07:22 ET